about
Understanding the role of the kynurenine pathway in human breast cancer immunobiologyThe potential for transition metal-mediated neurodegeneration in amyotrophic lateral sclerosisIron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents.Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron poolThiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progressionThe medicinal chemistry of novel iron chelators for the treatment of cancer.Major developments in the design of inhibitors along the kynurenine pathway.Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity.Characterisation of the kynurenine pathway in skin-derived fibroblasts and keratinocytes.The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.DNA nanoclew templated spherical nucleic acids for siRNA delivery.Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study.Inhibiting the kynurenine pathway in spinal cord injury: Multiple therapeutic potentials?Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox ActivityDevelopment of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor ScaffoldsLabel-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug DeliveryEffect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and growth2-hydroxy-1-naphthaldehyde 2-methylthiosemicarbazoneKynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic MechanismsCorrelation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau
P50
Q26773472-C816B056-E89B-4EDB-9BAF-E7B9BDE81416Q33938412-F6359B36-8558-4F1F-A31C-3C47E17D6864Q34458484-216D2BAB-4DA1-447E-BE1D-F0E1F945B6E2Q36673634-6BC1FC0D-B4BE-4EE6-8586-C833AED392D3Q37080926-F1923FDA-C20D-4E10-9AD3-5629DEA9D778Q37166121-4D6974B6-A12E-498D-9D05-012026656B88Q37338387-B3C62C52-228A-467A-83AD-900154372A79Q37550486-C1D9A81A-2254-47B5-9D39-96416CD3E27EQ37623145-6155E8D1-AD99-4990-96F2-65DFA284DB47Q37824720-4F33ACE7-12D4-4BF1-B7FB-82DC1C8D6EFEQ38808400-E4457050-CB8D-472F-8F47-D551DBA9CD6DQ38856007-14CA5347-1224-4C2E-96A8-DA604C7DF38AQ39302809-E9E48AE2-E4D5-4E04-9DA5-A8CC5E62A9A9Q39508023-BFD9AA57-DDC5-4817-96A3-0ACD9CA1751BQ39683790-91342D74-BD06-433A-9490-6A708A6868D8Q39884034-596FE7E3-A924-408F-83F6-B237BCF0B589Q40113365-4B1D883A-520C-42E2-8652-70BC0A850267Q40397762-7D66804B-3C9A-4990-8582-240284935FD2Q41499706-5FD82A7B-C291-407D-98DD-AEA924776E9EQ42933865-28DE2248-C1DB-4EA0-8F4F-3CBF4A4CD65EQ46193547-7500C949-3742-41B9-9E51-FC5B202332D2Q47586142-5F46E3FB-7C53-4ACF-B3D1-65A1025972C0Q52640685-AA63B609-9BAE-4C16-A878-A4681DE3C5DDQ55071408-1F23F9CB-204A-48E9-8C6C-6D7D813C8538Q57455048-544A5577-E3B4-4D5D-94EA-C1181E400A74Q61050477-B333749E-5087-4674-B4B9-004BDE165264Q61959965-AA2CB055-2BCC-41F5-9832-FD21FBAE0B83Q64445587-5355F1EF-4E8F-4736-8E4D-C113445113CCQ73691332-9A7EA3D4-28C9-4BBC-A8A0-18B0340C130FQ73704865-433B4D3E-BD8E-4A32-87E4-9FF8483872FAQ91150503-305890DB-F176-44B0-A317-D357B00D8853Q91761384-3DFD5A71-1F87-4AD8-87EC-A22497068DF6
P50
description
researcher
@en
wetenschapper
@nl
name
D B Lovejoy
@en
D B Lovejoy
@nl
type
label
D B Lovejoy
@en
D B Lovejoy
@nl
prefLabel
D B Lovejoy
@en
D B Lovejoy
@nl
P106
P31
P496
0000-0002-5331-8659